Simcere Pharmaceutical Group (SCR)

[Estrella]

$SIMC @ .0045!

[TheFinalCD]

Simcere Pharmaceutical Group Announces Shareholders' Approval of the Merger Agreement







Print


Alert



Simcere Pharmaceutical Grp. Simcere Pharmaceutical Grp. American Depositary Shares (NYSE:SCR)
Intraday Stock Chart

Today : Thursday 19 December 2013
Click Here for more Simcere Pharmaceutical Grp. Simcere Pharmaceutical Grp. American Depositary Shares Charts.

NANJING, China, Dec. 19, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that at an extraordinary general meeting held today, the Company's shareholders voted in favor of the proposal to authorize and approve the previously announced Agreement and Plan of Merger dated August 28, 2013 (the "Merger Agreement") among the Company, Simcere Holding Limited ("Parent") and Simcere Acquisition Limited ("Merger Sub"), pursuant to which Merger Sub will be merged with and into the Company with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), and any and all transactions contemplated by the Merger Agreement, including the Merger.

Approximately 81.6% of the Company's total outstanding ordinary shares voted in person or by proxy at today's extraordinary general meeting. Of these ordinary shares voted in person or by proxy at the extraordinary general meeting, approximately 99.84% were voted in favor of the proposal to authorize and approve the Merger Agreement and any and all transactions contemplated by the Merger Agreement, including the Merger.

The parties expect to complete the Merger as soon as practicable, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement. If the Merger is completed, the Company will become a privately held company and its American depositary shares will no longer be listed on the New York Stock Exchange.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:

Email: [e-mail]



In Nanjing:

Vivien Liang

Simcere Pharmaceutical Group

Tel: [phone] x 8857

In the United States:

Cindy Zheng

Brunswick Group LLC

Tel: [phone]





In Beijing:

Yue Yu

Brunswick Group

Tel: [phone]



SOURCE Simcere Pharmaceutical Group

Copyright 2013 PR Newswire

[surf1944]

6:32AM Simcere Pharma (thinly traded) announces sale of equity interest in Boda for a cash consideration of RMB400 mln (SCR) 9.69 : Co announces that it entered into a share transfer agreement with Zhuhai Rongding Equity Investment Partnership on June 17, 2013 to sell Simcere's ~99.99% equity interest in Jilin Boda pharmaceutical Co, which is currently the manufacturer of Yidasheng, for a cash consideration of RMB400 mln.

Simcere holds an ~99.99% stake in Boda through acquisitions made since 2007. Upon completion of this transaction, Simcere will no longer hold any equity interest in Boda.

[surf1944]

Simcere Pharmaceutical Group Announces its Special Committee's Engagement of Financial Advisor
Press Release: Simcere Pharmaceutical Group – Wed, Apr 3, 2013 6:00 AM EDT

NANJING, China, April 3, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that its Special Committee of the Board of Directors (the "Special Committee"), which was formed to consider a proposal by Mr. Jinsheng Ren, New Good Management Limited, Assure Ahead Investments Limited and its affiliates (the "Buyer Group"), pursuant to which the Buyer Group proposes to acquire all of the outstanding ordinary shares of the Company not currently owned by the Buyer Group, and any potential alternative transactions involving the Company, has retained UBS AG and/or its affiliates as its exclusive financial advisor to assist it in its work. No decisions have been made by the Special Committee with respect to the Company's response to the proposed transaction. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated.

[surf1944]

Simcere Pharma sells stake in Shanghai Celgen
Simcere Pharma sells stake in Shanghai Celgen Bio-Pharmaceutical for about $48 million

By The Associated Press | Associated Press – Tue, Jan 22, 2013 8:49 AM EST

Simcere Pharmaceutical Group has agreed to sell its stake in Shanghai Celgen Bio-Pharmaceutical Co. Ltd. for about 302 million yuan ($48.1 million).
The Chinese drug developer said Tuesday it entered into a share transfer agreement with Devont Asset Management Ltd. on Jan. 15 to sell its roughly 35 percent equity interest in Shanghai, which it acquired in 2009.
After the deal is completed, Simcere will no longer hold an equity interest in the company.
Simcere makes and sells pharmaceuticals in China, and focuses on the treatment of diseases that have high incidence or mortality rates like cancer, strokes or cardiovascular diseases.

[surf1944]

1:38AM Simcere Pharma receives approval from the FDA of China to begin first-in-man trials with APX003 (SCR) 8.02 : Apexigen announces that its partner, Simcere Pharmaceutical Group of Nanjing, received approval from the State Food and Drug Administration of China to begin first-in-man trials with APX003, which is also known as BD0801, for the treatment of cancer. With this approval, APX003/BD0801 becomes the first humanized monoclonal antibody derived from Apexigen's proprietary antibody technology platform to enter human trials.

[surf1944]

6:36AM Simcere Pharma announced the appointment of Hongquan Liu, as its CEO and Executive Director of the Board, effective October 8, 2012 (SCR) 7.52 : Co announced Jinsheng Ren will continue to serve as Chairman of Simcere. The Company also announced that Yehong Zhang, who currently serves as President of Simcere, will serve as CEO of Simcere MSD Pharmaceutical, the newly established joint venture between Simcere and Merck (MRK) effective from October 8, 2012. Dr. Zhang will no longer hold the position of President of Simcere. Between 2000 and 2012, Hongquan Liu held the positions of Director and General Manager of Sino-Swed Pharmaceutical.